Ha sido publicado un nuevo artículo que confirma los resultados de otros anteriores que observaban UN DESCENSO EN LA FRECUENCIA DEL CANCER DE MAMA ASOCIADA AL DESCENSO EN EL USO DE THS (Tratamiento Hormonal Sustitutorio)
Esta información me la ha enviado una colega de:REDCAPS: Red de mujeres profesionales para la salud. Solo quería compartirlo contigo:
la epidemia de la terapia hormonal sustitutiva en las mujeres, fue una epidemia silenciada
Changes in Invasive Breast Cancer and Ductal Carcinoma In Situ Rates in Relation to the Decline in Hormone Therapy Use
- Ghada N. Farhat, Rod Walker, Diana S.M. Buist, Tracy Onega and Karla Kerlikowske
+ Author Affiliations
From the San Francisco Coordinating Center, California Pacific Medical Center Research Institute; San Francisco Veterans Affairs Medical Center; University of California, San Francisco, San Francisco, CA; Group Health Research Institute, Seattle, WA; and Dartmouth Medical School, Norris Cotton Cancer Center, Lebanon, NH.
- Corresponding author: Karla Kerlikowske, MD, San Francisco Veterans Affairs Medical Center, General Internal Medicine Section, 111A1, 4150 Clement St, San Francisco, CA 94121; e-mail: firstname.lastname@example.org.
Purpose To assess trends in invasive breast cancer and ductal carcinoma in situ (DCIS) incidence in association with changes in hormone therapy (HT) use in regular mammography screeners.
Methods We included 2,071,814 screening mammography examinations performed between January 1997 and December 2006 on 696,385 women age 40 to 79 years; 9,586 breast cancers were diagnosed within 12 months of a screening examination. We calculated adjusted annual rates (mammogram level) for prevalent HT use, incident invasive breast cancer (overall and by tumor histology and estrogen receptor [ER] status), and incident DCIS.
Results After a precipitous decrease in HT use in 2002, the incidence of invasive breast cancer decreased significantly in 2002 to 2006 among women age 50 to 69 years (Ptrend(2002-2006) = .005) and 70 to 79 years (Ptrend(2002-2006) = .003) but not in women age 40 to 49 years (Ptrend(2002-2006) = .45). DCIS rates significantly decreased in women age 50 to 69 years after 2002 (Ptrend(2002-2006) = .02). Invasive ductal tumors significantly declined in women age 50 to 69 years and 70 to 79 years in 2002 to 2006. In women age 50 to 69 years, invasive lobular and ER-positive cancer rates declined steadily in 2002 to 2005 (Ptrend(2002-2005) = .02 and .03, respectively), but an elevated rate in 2006 rendered the overall trend nonsignificant (Ptrend(2002-2006) = .89 and .91, respectively).
Conclusion In parallel to the sharp decline in HT use in women undergoing regular mammography screening, invasive breast cancer rates decreased in women age 50 to 69 and 70 to 79 years after 2002, and DCIS rates decreased in women age 50 to 69 years, consistent with evidence that HT cessation reduces breast cancer risk. However, the decrease in incidence may have started to level off in 2006; this finding has not been uniformly reported in other populations, warranting further investigation.
Esta entrada fue publicada en Movimiento
. Guarda el enlace permanente